DRAD Digirad Corporation

Digirad Corporation is pleased to announce that Jamshid Maddahi, M.D., F.A.C.C., will serve as medical advisor (www.digirad.com) (NASDAQ:DRAD). Dr. Maddahi will advise Digirad on leading advances in nuclear cardiology SPECT (single photon emission computerized tomography) involving solid state detectors, fast imaging techniques and new clinical software. As an ICANL (Intersocietal Commission for the Accreditation of Nuclear Medicine Laboratories) certified reader, Dr. Maddahi will help Digirad develop a strategy to ensure that products and services meet future clinical requirements of nuclear cardiology. Dr. Maddahi will also play a pivotal role in working with Digirad�s new Cardius� 3 XPO triple-head cardiac gamma camera, which was unveiled in mid-2006 at the Society of Nuclear Medicine and American Society of Nuclear Cardiology meetings in San Diego and Montreal, respectively. The Cardius 3 XPO imaging systems feature new Solidium� high-definition solid-state (HDSD) digital detector technology, a new design allowing imaging of patients weighing up to 500 pounds, and up to 38 percent faster image acquisition times than conventional dual head systems. Since 1999, Dr. Maddahi has served as director of the Biomedical Imaging Institute in Los Angeles. He has been a clinical professor of medicine (cardiology) and clinical professor of molecular and medical pharmacology (nuclear medicine) at the David Geffen School of Medicine at UCLA since 1992 and 2004, respectively. A fellow of the American College of Cardiology, Dr. Maddahi has received numerous awards over the years, including Best Doctors in America; Best Doctors in Los Angeles; Certificate of Honor for Humanitarian Achievements, Hadassah Medical Center; Distinguished Scientist Award for distinguished contributions to nuclear medicine, Western Regional Society of Nuclear Medicine; and the UCLA Division of Cardiology Faculty Teaching Award. Dr. Maddahi has written or co-authored more than 300 manuscripts and abstracts covering a wide range of cardiology and nuclear medicine issues, and has served as a principal investigator or co-investigator for the American Heart Association, and the National Heart, Lung and Blood Institute. He is a founding member of both the American Society of Nuclear Cardiology and the American Society of Cardiac CT, and is a member of the Society of Nuclear Medicine, Academy of Molecular Imaging, American College of Cardiology, and American Heart Association Dr. Maddahi received a Doctor of Medicine degree from Tehran University School of Medicine in Tehran, Iran. He was a first and second year resident in internal medicine at the Illinois Masonic Medical Center at the University of Illinois; first and second year fellow in cardiology; and first and second year resident in nuclear medicine at Cedars-Sinai Medical Center, UCLA. About Digirad Digirad Corporation develops, manufactures and markets solid-state, digital gamma cameras to hospitals, imaging centers and physician offices. Digirad offers a comprehensive line of solid-state nuclear gamma cameras that produce high-quality images for use in the detection of many medical conditions, including cardiovascular disease. Digirad's cameras are unique as their lightweight and compact design allows them to fit easily into small office spaces. Digirad's wholly owned subsidiary, Digirad Imaging Solutions (DIS), offers a comprehensive, mobile imaging leasing and services program for physicians who wish to perform in-office nuclear cardiology procedures but do not have the patient volume, capital or resources to justify purchasing a gamma camera. For more information, please visit www.digirad.com. Digirad�, Digirad Imaging Solutions�, and Cardius� are registered trademarks of Digirad Corporation. Forward-Looking Statements Digirad cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. You can identify these statements by the fact that they do not relate strictly to historical or current facts and use words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" and other words and terms of similar meaning in connection with a discussion of future operating or financial performance or events. Examples of such statements include statements regarding the quality and features of the Cardius� 3 XPO imaging system and Dr. Maddahi�s ability to assist Digirad in developing a strategy to ensure that products and services meet future clinical requirements of nuclear cardiology. The inclusion of these and other forward-looking statements should not be regarded as a representation by Digirad that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Digirad's business detailed in Digirad's Securities and Exchange Commission filings, including its Annual Report on Form 10-K and other reports filed with the Securities and Exchange Commission. Given these uncertainties, readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Digirad undertakes no obligation to revise or update this press release including the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.